This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Lymphoid neoplasms | |
|---|---|
| Name | Lymphoid neoplasms |
| Field | Hematology, Oncology |
Lymphoid neoplasms are a heterogeneous group of malignancies arising from lymphoid lineage cells within the immune system, encompassing diseases that affect lymphocytes and plasma cells. These disorders span a spectrum from indolent to highly aggressive clinical courses and intersect with disciplines including hematology, oncology, and pathology. Care pathways typically involve institutions such as Mayo Clinic, Memorial Sloan Kettering Cancer Center, and Dana-Farber Cancer Institute and reference staging frameworks developed by organizations like the World Health Organization and the American Joint Committee on Cancer.
Lymphoid neoplasms include neoplastic proliferations historically described under eponymous classifications by figures such as Thomas Hodgkin, Karl Landsteiner, and William Osler, and codified by committees including the World Health Organization and the International Agency for Research on Cancer. Modern management integrates diagnostics from centers such as Johns Hopkins Hospital, Cleveland Clinic, and St Jude Children's Research Hospital, and therapeutic approaches influenced by trials conducted at cooperative groups like the European Organisation for Research and Treatment of Cancer and the National Cancer Institute. Epidemiologic surveillance often references registries maintained by institutions including Surveillance, Epidemiology, and End Results Program, Cancer Research UK, and the Centers for Disease Control and Prevention.
Contemporary classification derives from the 2016 and subsequent updates of the World Health Organization classification, distinguishing major categories such as mature B-cell neoplasms, mature T- and NK-cell neoplasms, precursor lymphoid neoplasms, and plasma cell neoplasms. Examples include entities historically named after clinicians—Thomas Hodgkin for nodular sclerosis variants—and molecularly defined tumors characterized in studies at institutions such as Broad Institute and Sanger Institute. Subclassification uses clinicopathologic schemes developed by societies like the European Society for Medical Oncology and the American Society of Clinical Oncology.
Pathogenetic mechanisms integrate oncogenic events described in landmark studies from laboratories affiliated with Harvard Medical School, Massachusetts Institute of Technology, and Cold Spring Harbor Laboratory. Viral oncogenesis links to agents such as Epstein–Barr virus, Human T-lymphotropic virus 1, and associations explored by researchers at Osaka University and University of Tokyo. Genetic lesions including translocations (e.g., t(14;18)) and mutations identified by consortia like the International Cancer Genome Consortium and publications from The Cancer Genome Atlas underpin malignant transformation. Immune dysregulation observed in cohorts from Karolinska Institute and Imperial College London contributes to susceptibility, with environmental and occupational exposures studied in collaborations involving World Health Organization and national public health agencies.
Clinical manifestations range from painless lymphadenopathy and B symptoms documented in case series from Mayo Clinic to extranodal involvement described in reports from MD Anderson Cancer Center and Royal Marsden Hospital. Diagnostic pathways integrate imaging modalities such as PET-CT protocols standardized by the European Association of Nuclear Medicine and histologic confirmation via excisional biopsy interpreted using criteria promulgated by the College of American Pathologists. Laboratory assays developed at centers like Quest Diagnostics and Laboratory Corporation of America include flow cytometry panels and molecular tests guided by guidelines from the American Society for Clinical Pathology.
Morphologic assessment employs techniques refined in departments at Johns Hopkins Hospital and Mayo Clinic, with immunophenotypic classification relying on marker panels standardized by the World Health Organization and the College of American Pathologists. Immunohistochemistry and flow cytometry detect lineage-defining antigens (e.g., CD20, CD3) using reagents manufactured by companies such as Roche, Dako, and BD Biosciences, while cytogenetic studies utilize platforms developed at European Molecular Biology Laboratory and sequencing infrastructures at Broad Institute.
Staging systems include adaptations of the Ann Arbor system refined through consensus meetings hosted by institutions like Mount Sinai Health System and the Royal College of Physicians. Prognostic indices—such as the International Prognostic Index—were derived from multicenter analyses led by groups including the Ludwig Institute for Cancer Research and the German Hodgkin Study Group. Biomarkers predictive of outcome have been validated in cohorts from International Lymphoma Study Group and trials coordinated by the National Cancer Institute.
Therapeutic strategies encompass chemoimmunotherapy regimens first tested in trials at National Institutes of Health and expanded through cooperative groups such as the Children's Oncology Group and the European Organisation for Research and Treatment of Cancer. Monoclonal antibodies pioneered by biotechnology firms like Genentech and Roche and cellular therapies developed by centers including University of Pennsylvania (chimeric antigen receptor T cells) have transformed outcomes for certain subtypes. Radiation oncology approaches reference protocols from the American Society for Radiation Oncology and surgical interventions are performed at tertiary centers such as Cleveland Clinic.
Incidence and survival statistics are reported by registries including Surveillance, Epidemiology, and End Results Program and Cancer Research UK, with demographic patterns analyzed in studies from Harvard T.H. Chan School of Public Health and Johns Hopkins Bloomberg School of Public Health. Outcomes have improved in many subtypes following advances documented in trials led by National Cancer Institute and cooperative groups, while global disparities in care are the focus of initiatives by World Health Organization and non-governmental organizations such as Doctors Without Borders.
Category:Hematologic malignancies